Century Therapeutics

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.

Century Therapeutics Added to the NASDAQ Biotechnology Index

- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 -

Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

Lead program, CNTY-101 in relapsed/refractory non-Hodgkin's lymphoma, remains on track for IND filing in mid-2022

Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Collaboration enables Century to explore Outpace's protein solutions for cell therapy to enhance functionality of iPSC platform

Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021, according to the preliminary list of IPO additions to the Russell indexes.

Century Therapeutics Announces Its Addition to the Russell 2000® Index

Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221M June 30, 2021 cash, cash equivalents, and marketable securities of $440M

Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Century, were approximately $242.7 million. All the shares of common stock were offered by Century.

Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Atai Life Sciences BV

Ambrx Biopharma Inc

Cyteir Therapeutics

Codex DNA

Femasys

Going public on Friday: atai Life Sciences, Ambrx Biopharma, Century Therapeutics, Codex DNA, Cyteir Therapeutics, and Femasys.

Peter Thiel's Atai Life Sciences and 5 Other Companies List Shares

PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of its common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Century. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Century, are expected to be $211.0 million. Century's common stock is expected to begin trading on the Nasdaq Global Select Market on June 18, 2021 under the ticker symbol “IPSC”. The offering is expected to close on June 22, 2021, subject to the satisfaction of customary closing conditions. In addition, Century has granted the underwriters a 30-day option to purchase up to an additional 1,582,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

Century Therapeutics Announces Pricing of Initial Public Offering

News for Century Therapeutics Stock (IPSC)